Editor
Partner
When a business resolution isn’t possible, the choice of forum shapes everything that follows. This recorded webcast compares mediation, litigation, and arbitration across the factors that matter most — timing, cost, confidentiality, discovery, motion practice, and appellate rights — and compares the strategic advantages and trade-offs each path presents.
Join Gibson Dunn lawyers for the first recorded session of a three-part series following a single life sciences collaboration and licensing dispute across its full lifecycle to explore how contract language, forum selection, and science shape leverage, timing, proof, and outcomes.
Recent shifts in international trade policies have led to the imposition of new tariffs prompting life science companies to reassess their license agreements to understand the potential impact of these new tariffs on royalty calculations under such agreements.
Dear friends and colleagues, We are excited to introduce Biotech Briefings, providing Gibson Dunn’s commentary and perspectives on the legal, business, and regulatory issues shaping the life sciences industry. From groundbreaking developments in biopharma, medical devices, and diagnostics to the evolving landscape of IP, FDA and SEC regulation, Biotech Briefings delivers timely insights for companies,…